Growing community of inventors

Parlin, NJ, United States of America

Jonathan Brazaitis

Average Co-Inventor Count = 3.09

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 72

Jonathan BrazaitisGrant E Gallagher (9 patents)Jonathan BrazaitisRaymond Yu (9 patents)Jonathan BrazaitisJoyce Eskdale (1 patent)Jonathan BrazaitisJonathan Brazaitis (9 patents)Grant E GallagherGrant E Gallagher (25 patents)Raymond YuRaymond Yu (11 patents)Joyce EskdaleJoyce Eskdale (10 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Medical Diagnostic Laboratories, LLC (9 from 75 patents)


9 patents:

1. RE49026 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof

2. 10416172 - Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling

3. 9868776 - Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases

4. 9605027 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof

5. 9523073 - Elisa for a naturally-occurring soluble truncated form of IL-23 receptor

6. 9187750 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases

7. 9169292 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof

8. 8946150 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof

9. 8618070 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/25/2025
Loading…